Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
Bristol Myers Squibb r&d expenses
Research and development expenses are spending on new products and technology.
Bristol Myers Squibb's R&D Expenses for the twelve months ending Sep 30, 2026 was $10.56B, up 0.0% year over year. For fiscal 2025 it was $9.95B, down 10.8% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $11.16B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.95B | -10.8% |
| FY2024 | Dec 31, 2024 | $11.16B | +20.0% |
| FY2023 | Dec 31, 2023 | $9.30B | -2.2% |
| FY2022 | Dec 31, 2022 | $9.51B | -6.7% |
| FY2021 | Dec 31, 2021 | $10.20B | +1.5% |
| FY2020 | Dec 31, 2020 | $10.05B | +63.4% |
| FY2019 | Dec 31, 2019 | $6.15B | -2.9% |
| FY2018 | Dec 31, 2018 | $6.33B | -2.1% |
| FY2017 | Dec 31, 2017 | $6.47B | +29.1% |
| FY2016 | Dec 31, 2016 | $5.01B | -15.3% |
| FY2015 | Dec 31, 2015 | $5.92B | +30.6% |
| FY2014 | Dec 31, 2014 | $4.53B | +21.5% |
| FY2013 | Dec 31, 2013 | $3.73B | -4.4% |
| FY2012 | Dec 31, 2012 | $3.90B | +1.7% |
| FY2011 | Dec 31, 2011 | $3.84B | +7.7% |
| FY2010 | Dec 31, 2010 | $3.57B | -2.2% |
| FY2009 | Dec 31, 2009 | $3.65B | +3.8% |
| FY2008 | Dec 31, 2008 | $3.51B | +11.1% |
| FY2007 | Dec 31, 2007 | $3.16B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.37B | -6.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.96B | +14.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.65B | +17.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.59B | -19.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.53B | +6.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.58B | -11.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.26B | -16.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.19B | +28.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.37B | +5.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.90B | +28.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.70B | +16.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.48B | -1.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.24B | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.26B | -2.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.32B | +2.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.51B | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.42B | -18.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.32B | -6.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.26B | +1.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.52B | -5.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.98B | +19.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.48B | -1.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.22B | -6.5% |
| Q4 FY2020 | Dec 31, 2020 | $2.66B | +26.6% |
| Q3 FY2020 | Sep 30, 2020 | $2.50B | +81.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.52B | +90.3% |
| Q1 FY2020 | Mar 31, 2020 | $2.37B | +76.0% |
| Q4 FY2019 | Dec 31, 2019 | $2.10B | +53.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.38B | +7.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.33B | -45.6% |
| Q1 FY2019 | Mar 31, 2019 | $1.35B | +7.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.37B | -29.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.28B | -18.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.44B | +45.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.25B | -4.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.93B | +30.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.56B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.68B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.30B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.47B | – |
See a number that looks wrong?